---
layout: default
title: Iron
parent: 僅模型預測 (L5)
nav_order: 545
evidence_level: L5
indication_count: 10
---

# Iron
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Iron: From Iron Deficiency Anaemia to Vitamin B12- and Folate-Independent Constitutional Megaloblastic Anaemia

## One-Sentence Summary

Iron (elemental iron, DrugBank DB01592) is an essential mineral supplement with a long-established clinical role in correcting iron deficiency and treating iron deficiency anaemia.
The TxGNN model predicts it may be effective for **Vitamin B12- and Folate-Independent Constitutional Megaloblastic Anaemia**, with a high model confidence of **99.89%**; however, this prediction is currently supported by **no clinical trials** and **no published literature**, placing it at the lowest evidence tier (L5).

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Iron deficiency anaemia |
| Predicted New Indication | Vitamin B12- and Folate-Independent Constitutional Megaloblastic Anaemia |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 — Model prediction only, no actual studies |
| Singapore Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known pharmacological information, Iron is an essential trace mineral whose primary therapeutic mechanism involves replenishing depleted iron stores, enabling haemoglobin synthesis, and supporting cellular oxygen transport via iron-containing proteins (haemoglobin, myoglobin, cytochromes). Its efficacy in treating iron deficiency and iron deficiency anaemia has been proven across decades of clinical use and is supported by extensive Phase 3 and Phase 4 evidence globally.

Vitamin B12- and folate-independent constitutional megaloblastic anaemia is a rare, genetically determined disorder characterised by impaired DNA replication in erythroid precursors, resulting in abnormally large, dysfunctional red blood cells. By definition, this condition is not caused by deficiencies in vitamin B12 or folate metabolism, which makes its aetiology distinct from more common forms of megaloblastic anaemia. The molecular basis of this constitutional subtype remains incompletely understood.

The mechanistic connection between iron supplementation and this specific form of megaloblastic anaemia is extremely tenuous. Iron deficiency classically causes microcytic, hypochromic anaemia — physiologically the opposite of macrocytic megaloblastic anaemia. Although iron serves as a cofactor in certain DNA synthesis enzymes (e.g., ribonucleotide reductase), no direct mechanistic link to this constitutional subtype has been established in any clinical or preclinical study. The TxGNN model's high confidence score (99.89%) most plausibly reflects knowledge-graph over-generalisation via shared "anaemia" disease nodes in the bipartite network, rather than a genuine therapeutic signal. This prediction is not supported by any existing clinical or basic science evidence.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this indication.

---

## Literature Evidence

Currently no related literature available for this indication.

---

## Singapore Market Information

Iron (DB01592) is not currently registered in Singapore. No product authorisation records are available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This is an L5-level prediction with no supporting clinical trials or published literature, and the mechanistic rationale is physiologically contradictory — iron deficiency produces microcytic anaemia, not megaloblastic anaemia. The TxGNN model's high score most likely reflects knowledge-graph over-generalisation rather than a clinically meaningful repurposing signal.

**To proceed, the following is needed:**
- A credible and biologically plausible mechanistic hypothesis explaining how iron supplementation could address B12/folate-independent megaloblastosis (e.g., via iron's role in ribonucleotide reductase or other DNA repair enzymes)
- At minimum, preclinical (cell or animal model) or case-report evidence demonstrating iron's effect in this specific anaemia subtype
- Retrieval of detailed mechanism of action data from DrugBank (currently unavailable)
- Review of regulatory package insert safety data, including key warnings and contraindications (currently unavailable)
- Consultation with a haematologist specialising in constitutional anaemias before any further investment in this direction
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

